Effects of Calcium Fructoborate on Levels of C-Reactive Protein, Total Cholesterol, Low-Density Lipoprotein, Triglycerides, IL-1β, IL-6, and MCP-1: a Double-blind, Placebo-controlled Clinical Study

Biological Trace Element Research

Volumn 163, Issue 1-2, 2015, Pages 124-131

  Rogoveanu, Otilia Constantina ^a   Mogoşanu, George Dan ^a   Bejenaru, Cornelia ^a   Bejenaru, Ludovic Everard ^a   Croitoru, Octavian ^a   Neamţu, Johny ^a   Pietrzkowski, Zbigniew ^b   Reyes Izquierdo, Tania ^b   Biţă, Andrei ^c   Scorei, Iulia Daria ^c   Scorei, Romulus Ion ^c  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^b Futureceuticals   (United States)

^c Bioboron Research Institute   (Romania)

Author keywords

Blood lipids; Calcium fructoborate; Clinical trial; IL 1 ; IL 6; MCP 1; Triglycerides

Indexed keywords

C REACTIVE PROTEIN; CALCIUM DERIVATIVE; CALCIUM FRUCTOBORATE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BORIC ACID; CCL2 PROTEIN, HUMAN; FRUCTOSE; IL1B PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN TRIGLYCERIDE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; MALE; NORMAL HUMAN; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; BLOOD; METABOLISM; MIDDLE AGED; TIME;

ADULT; BORATES; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; TIME FACTORS; TRIGLYCERIDES;

EID: 84922105213     PISSN: 01634984     EISSN: 15590720     Source Type: Journal    
DOI: 10.1007/s12011-014-0155-9     Document Type: Article

References (38)

1. Miljkovic D, Scorei RI, Cimpoiaşu VM, Scorei ID (2009) Calcium fructoborate: plant-based dietary boron for human nutrition. J Diet Suppl 6:211–226. doi:10.1080/19390210903070772
2. Scorei IR, Ciofrangeanu C, Ion R, Cimpean A, Galateanu B, Mitran V, Iordachescu D (2010) In vitro effects of calcium fructoborate upon production of inflammatory mediators by LPS-stimulated RAW 264.7 macrophages. Biol Trace Elem Res 135:334–344. doi:10.1007/s12011-009-8488-5
3. Scorei ID, Scorei IR (2013) Calcium fructoborate helps control inflammation associated with diminished bone health. Biol Trace Elem Res 155:315–321. doi:10.1007/s12011-013-9800-y
4. Scorei IR, Mitrut P, Petrisor I, Scorei ID (2011) A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructoborate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritis. Biol Trace Elem Res 144:253–263. doi:10.1007/s12011-011-9083-0
5. Reyes-Izquierdo T, Phelan MJ, Keller R, Argumedo R, Shu C, Pietrzkowski Z (2014) Short therm efficacy of a combination of glucosamine and chondroitin sulfate compared to a combination of glucosamine, chondroitin sulfate and calcium fructoborate (CFB) on improvement of knee discomfort conditions in healthy subjects. A comparative, double-blind, placebo controlled acute clinical study. JARCP (in press)
6. Reyes-Izquierdo T, Nemzer B, Gonzalez AE, Zhou Q, Argumedo R, Shu C, Pietrzkowski Z (2012) Short-term intake of calcium fructoborate improves WOMAC and McGill scores and beneficially modulates biomarkers associated with knee osteoarthritis: a pilot clinical double-blinded placebo-controlled study. Am J Biomed Sci 4:111–122. doi:10.5099/aj120200111
7. Scorei IR (2011) Calcium fructoborate: plant-based dietary boron as potential medicine for cancer therapy. Front Biosci (Schol Ed) 3:205–215
8. Militaru C, Donoiu I, Craciun A, Scorei ID, Bulearca AM, Scorei RI (2013) Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition 29:178–183. doi:10.1016/j.nut.2012.07.006
9. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387–1397. doi:10.1056/NEJMoa032804
10. Li JJ, Fang CH (2004) C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 62:499–506. doi:10.1016/j.mehy.2003.12.014
11. Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126. doi:10.1056/NEJM199901143400207
12. Packard RR, Libby P (2008) Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 54:24–38. doi:10.1373/clinchem.2007.097360
13. Armstrong EJ, Morrow DA, Sabatine MS (2006) Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation 113:e72–e75. doi:10.1161/CIRCULATIONAHA.105.595520
14. Yoldas T, Gonen M, Godekmerdan A, Ilhan F, Bayram E (2007) The serum high-sensitive C reactive protein and homocysteine levels to evaluate the prognosis of acute ischemic stroke. Mediat Inflamm 2007:15929. doi:10.1155/2007/15929
15. Bhupathiraju SN, Alekel DL, Stewart JW, Hanson LN, Shedd KM, Reddy MB, Hanson KB, Van Loan MD, Genschel U, Koehler KJ (2007) Relationship of circulating total homocysteine and C-reactive protein to trabecular bone in postmenopausal women. J Clin Densitom 10:395–403. doi:10.1016/j.jocd.2007.06.002
16. Khandanpour N, Loke YK, Meyer FJ, Jennings B, Armon MP (2009) Homocysteine and peripheral arterial disease: systematic review and meta-analysis. Eur J Vasc Endovasc Surg 38:316–322. doi:10.1016/j.ejvs.2009.05.007
17. Wierzbicki AS (2007) Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res 4:143–150. doi:10.3132/dvdr.2007.033
18. Su D, Li Z, Li X, Chen Y, Zhang Y, Ding D, Deng X, Xia M, Qiu J, Ling W (2013) Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease. Mediat Inflamm 2013:726178. doi:10.1155/2013/726178
19. Vicenová B, Vopálenský V, Burýsek L, Pospísek M (2009) Emerging role of interleukin-1 in cardiovascular diseases. Physiol Res 58:481–498
20. World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194. doi:10.1001/jama.2013.281053
21. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease (2011) Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123:2292–2333. doi:10.1161/CIR.0b013e3182160726
22. Takahashi M, Masuyama J, Ikeda U, Kasahara T, Kitagawa S, Takahashi Y, Shimada K, Kano S (1995) Induction of monocyte chemoattractant protein-1 synthesis in human monocytes during transendothelial migration in vitro. Circ Res 76:750–757. doi:10.1161/01.RES.76.5.750
23. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM (1990) Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 87:5134–5138
24. Sung FL, Slow YL, Wang G, Lynn EG, Karmin O (2001) Homocysteine stimulates the expression of monocyte chemoattractant protein-1 in endothelial cells leading to enhanced monocyte chemotaxis. Mol Cell Biochem 216:121–128. doi:10.1023/A:1017383916068
25. Shyy YJ, Hsieh HJ, Usami S, Chien S (1994) Fluid shear stress induces a biphasic response of human monocyte chemotactic protein 1 gene expression in vascular endothelium. Proc Natl Acad Sci U S A 91:4678–4682
26. Ikeda U, Matsui K, Murakami Y, Shimada K (2002) Monocyte chemoattractant protein-1 and coronary artery disease. Clin Cardiol 25:143–147. doi:10.1002/clc.4960250403
27. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Natoli E, Rollins BJ, Milos PM (1999) Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 19:1518–1525. doi:10.1161/01.ATV.19.6.1518
28. Reckless J, Rubin EM, Verstuyft JB, Metcalfe JC, Grainger DJ (1999) Monocyte chemoattractant protein-1 but not tumor necrosis factor-alpha is correlated with monocyte infiltration in mouse lipid lesions. Circulation 99:2310–2316. doi:10.1161/01.CIR.99.17.2310
29. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF (1999) MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103:773–778. doi:10.1172/JCI5624
30. Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Frøland SS, Gullestad L (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100:614–620. doi:10.1161/01.CIR.100.6.614
31. Hojo Y, Ikeda U, Takahashi M, Shimada K (2002) Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis 161:403–408. doi:10.1016/S0021-9150(01)00636-0
32. Gonzalez-Quesada C, Frangogiannis NG (2009) Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes. Curr Atheroscler Rep 11:131–138. doi:10.1007/s11883-009-0021-y
33. Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874. doi:10.1038/nature01323
34. Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:317–325. doi:10.1038/nature10146
35. von der Thüsen JH, Kuiper J, van Berkel TJ, Biessen EA (2003) Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 55:133–166. doi:10.1124/pr.55.1.5
36. Pudil R, Tichý M, Andrýs C, Rehácek V, Bláha V, Vojácek J, Palicka V (2010) Plasma interleukin-6 level is associated with NT-proBNP level and predicts short- and long-term mortality in patients with acute heart failure. Acta Med (Hradec Kralove) 53:225–228
37. Lee JK, Bettencourt R, Brenner D, Le TA, Barrett-Connor E, Loomba R (2012) Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study. PLoS ONE 7:e34218. doi:10.1371/journal.pone.0034218
38. Wang M, Jin W, Guo AM, Stubbe J (2013) Cardiovascular inflammation. Mediat Inflamm 2013:123513. doi:10.1155/2013/123513